Limits...
Expression and clinicopathological significance of FSIP1 in breast cancer.

Zhang H, Luo M, Jin Z, Wang D, Sun M, Zhao X, Zhao Z, Lei H, Li M, Liu C - Oncotarget (2015)

Bottom Line: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001).Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003).Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

View Article: PubMed Central - PubMed

Affiliation: Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, China.

ABSTRACT

Aim: To investigate the clinicopathological significance of the expression of fibrous sheath interacting protein 1 (FSIP1) in breast cancer, serum samples, and wound fluid from patients with breast cancer.

Methods: Wound fluid and serum samples from female patients with primary breast cancer, recurrent and metastatic breast cancer, and benign tumors were analyzed for FSIP1 expression using ELISA. 286 paraffin-embedded surgical specimens from breast cancer patients with at least 5 years of follow-up were included for FSIP1 expression assay using immunohistochemistry.

Results: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001). Strong correlation was observed between FSIP1 expression and human epidermal growth factor receptor 2 (Her-2) or Ki67 expression in breast cancer (p = 0.027 and 0.002, respectively). Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003). Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

Conclusion: FSIP1 may play an important role in the tumorigenesis and invasion of breast cancer and is a potential biomarker for breast cancer diagnosis or prognosis.

No MeSH data available.


Related in: MedlinePlus

FSIP1 expression level in wound fluid after surgery(A) There was no difference in FSIP1 level between wound fluid and serum of patients with primary breast cancer (p = 0.0613). (B) FSIP1 level in wound fluid of patients with negative lymph nodes was higher than those of patients with positive lymph nodes (p = 0.0384).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496383&req=5

Figure 4: FSIP1 expression level in wound fluid after surgery(A) There was no difference in FSIP1 level between wound fluid and serum of patients with primary breast cancer (p = 0.0613). (B) FSIP1 level in wound fluid of patients with negative lymph nodes was higher than those of patients with positive lymph nodes (p = 0.0384).

Mentions: No difference in the levels of FSIP1 between the wound fluid and serum sample of patients with primary breast cancer was observed (4, 613 ± 3, 612 pg/ml vs. 4, 713 ± 3, 065 pg/ml, p = 0.0613) (Figure 4A). However, FSIP1 expression in the wound fluid from patients with negative lymph nodes was significantly higher than in wound fluid from patients with positive lymph nodes (4, 937 ± 2, 914 pg/ml vs. 3, 273 ± 2, 647 pg/ml, p = 0.0384; Figure 4B).


Expression and clinicopathological significance of FSIP1 in breast cancer.

Zhang H, Luo M, Jin Z, Wang D, Sun M, Zhao X, Zhao Z, Lei H, Li M, Liu C - Oncotarget (2015)

FSIP1 expression level in wound fluid after surgery(A) There was no difference in FSIP1 level between wound fluid and serum of patients with primary breast cancer (p = 0.0613). (B) FSIP1 level in wound fluid of patients with negative lymph nodes was higher than those of patients with positive lymph nodes (p = 0.0384).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496383&req=5

Figure 4: FSIP1 expression level in wound fluid after surgery(A) There was no difference in FSIP1 level between wound fluid and serum of patients with primary breast cancer (p = 0.0613). (B) FSIP1 level in wound fluid of patients with negative lymph nodes was higher than those of patients with positive lymph nodes (p = 0.0384).
Mentions: No difference in the levels of FSIP1 between the wound fluid and serum sample of patients with primary breast cancer was observed (4, 613 ± 3, 612 pg/ml vs. 4, 713 ± 3, 065 pg/ml, p = 0.0613) (Figure 4A). However, FSIP1 expression in the wound fluid from patients with negative lymph nodes was significantly higher than in wound fluid from patients with positive lymph nodes (4, 937 ± 2, 914 pg/ml vs. 3, 273 ± 2, 647 pg/ml, p = 0.0384; Figure 4B).

Bottom Line: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001).Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003).Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

View Article: PubMed Central - PubMed

Affiliation: Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, China.

ABSTRACT

Aim: To investigate the clinicopathological significance of the expression of fibrous sheath interacting protein 1 (FSIP1) in breast cancer, serum samples, and wound fluid from patients with breast cancer.

Methods: Wound fluid and serum samples from female patients with primary breast cancer, recurrent and metastatic breast cancer, and benign tumors were analyzed for FSIP1 expression using ELISA. 286 paraffin-embedded surgical specimens from breast cancer patients with at least 5 years of follow-up were included for FSIP1 expression assay using immunohistochemistry.

Results: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001). Strong correlation was observed between FSIP1 expression and human epidermal growth factor receptor 2 (Her-2) or Ki67 expression in breast cancer (p = 0.027 and 0.002, respectively). Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003). Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

Conclusion: FSIP1 may play an important role in the tumorigenesis and invasion of breast cancer and is a potential biomarker for breast cancer diagnosis or prognosis.

No MeSH data available.


Related in: MedlinePlus